Validation Data Gallery
Filter:
Tested Applications
| Positive WB detected in | NIH/3T3 cells |
| Positive IP detected in | NIH/3T3 cells |
| Positive IHC detected in | human kidney tissue, human breast cancer tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:200-1:1000 |
| Immunoprecipitation (IP) | IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate |
| Immunohistochemistry (IHC) | IHC : 1:50-1:500 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Published Applications
| KD/KO | See 3 publications below |
| WB | See 89 publications below |
| IHC | See 3 publications below |
| IF | See 2 publications below |
| IP | See 1 publications below |
| CoIP | See 1 publications below |
Product Information
17670-1-AP targets JAK2 in WB, IHC, IF, IP, CoIP, ELISA applications and shows reactivity with human, mouse samples.
| Tested Reactivity | human, mouse |
| Cited Reactivity | human, mouse, rat, pig, zebrafish |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen | JAK2 fusion protein Ag11264 相同性解析による交差性が予測される生物種 |
| Full Name | Janus kinase 2 (a protein tyrosine kinase) |
| Calculated molecular weight | 1132 aa, 130 kDa |
| Observed molecular weight | 120-130 kDa |
| GenBank accession number | BC039695 |
| Gene Symbol | JAK2 |
| Gene ID (NCBI) | 3717 |
| RRID | AB_2811138 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | O60674 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol , pH 7.3 |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
Janus kinases (JAKs) are non-receptor tyrosine kinases that are activated by cytokine binding to cytokine receptors resulting in stimulation of the JAK-STAT signaling pathway. Aberrant activation of this signaling pathway is associated with numerous immune disorders and cancer.
Protocols
| Product Specific Protocols | |
|---|---|
| WB protocol for JAK2 antibody 17670-1-AP | Download protocol |
| IHC protocol for JAK2 antibody 17670-1-AP | Download protocol |
| IP protocol for JAK2 antibody 17670-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
| Species | Application | Title |
|---|---|---|
Adv Healthc Mater Dual-Barb Microneedle with JAK/STAT Inhibitor-Loaded Nanovesicles Encapsulation for Tendinopathy | ||
J Neuroinflammation Kynurenic acid blunts A1 astrocyte activation against neurodegeneration in HIV-associated neurocognitive disorders | ||
Cell Death Dis 4EBP1 senses extracellular glucose deprivation and initiates cell death signaling in lung cancer | ||
Theranostics Combination therapy with ropivacaine-loaded liposomes and nutrient deprivation for simultaneous cancer therapy and cancer pain relief. | ||
Arch Med Res Extracellular Vesicles from Carcinoma-associated Fibroblasts Promote EMT of Salivary Adenoid Cystic Carcinoma Via IL-6 | ||
Biomed Pharmacother Molecular mechanism through which Tripterygium hypoglaucum (Lévl.) Hutch alleviates psoriasis |